Analyst Price Targets — KNSA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 16, 2026 12:35 pm | — | Wedbush | $58.00 | $46.25 | TheFly | Kiniksa price target raised to $58 from $53 at Wedbush |
| February 19, 2026 10:35 am | — | Canaccord Genuity | $62.00 | $45.39 | TheFly | Kiniksa initiated with a Buy at Canaccord |
| January 13, 2026 1:42 pm | David Nierengarten | Wedbush | $50.00 | $39.65 | TheFly | Kiniksa price target raised to $50 from $48 at Wedbush |
| October 29, 2025 11:34 am | — | Goldman Sachs | $55.00 | $37.81 | TheFly | Kiniksa price target raised to $55 from $45 at Goldman Sachs |
| October 13, 2025 11:24 am | — | Wedbush | $44.00 | $37.89 | TheFly | Kiniksa price target raised to $44 from $38 at Wedbush |
| July 29, 2025 5:30 pm | — | Jefferies | $54.00 | $30.37 | TheFly | Kiniksa price target raised to $54 from $45 at Jefferies |
| October 29, 2024 4:23 pm | Liisa Bayko | Evercore ISI | $35.00 | $23.27 | StreetInsider | Kiniksa (KNSA) PT Raised to $35 at Evercore ISI |
| September 13, 2024 3:31 am | Roger Song | Jefferies | $40.00 | $24.49 | StreetInsider | Jefferies Starts Kiniksa (KNSA) at Buy |
| May 3, 2024 7:18 am | Eva Fortea Verdejo | Wells Fargo | $34.00 | $19.38 | StreetInsider | Wells Fargo Starts Kiniksa (KNSA) at Overweight, 'we see +15-25% upside potential' |
Latest News for KNSA
The chief accounting officer of Kiniksa Pharmaceuticals sold 6,625 shares for roughly $309,000 on April 9, 2026. The director reported still holding 27,418 Class A ordinary shares after the transaction.
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) COO Ross Moat sold 1,703 shares of the firm's stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $79,513.07. Following the sale, the chief operating officer directly owned 12,029 shares of the
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by clicking on this link – LONDON, April 08, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for…
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.03 and last traded at $49.55, with a volume of 790616 shares trading hands. The stock had previously closed at $48.82. Analysts Set New Price Targets A number of
Aberdeen Group plc grew its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) by 152.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 400,598 shares of the company's stock after acquiring an additional 241,876 shares during the quarter.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KNSA.
U.S. House Trading
No House trades found for KNSA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.